Modulating BRICHOS for an Alzheimer’s Therapy
| Reference number | |
| Coordinator | Karolinska Institutet - Institutionen för Neurobiologi, Vårdvetenskap och Samhälle (NVS), H1 |
| Funding from Vinnova | SEK 2 000 000 |
| Project duration | October 2018 - January 2022 |
| Status | Completed |
| Venture | Eurostars |
Important results from the project
The aim was to show that the monomeric form of recombinant Bri2 BRICHOS has potential as a treatment for Alzheimer´s disease. This has been fulfilled to the extent that we have shown that a mutated form of Bri2 BRICHOS that is stabilized in its monomeric form works with intravenous treatment in Alzheimer´s mice.
Expected long term effects
We expected monomeric Bri2 BRICHOS to work and this proved to be the case with intravenous treatment.
Approach and implementation
The setup with parallel tracks in terms of biochemistry, animal models and NMR-based screening was useful because, above all, biochemistry and structure-based screening complemented each other.